FDA panel backs Breo adult asthma use; rejects adolescents
This article was originally published in Scrip
Executive Summary
An FDA panel on 19 March backed the use of GlaxoSmithKline's Breo Ellipta (fluticasone furoate/vilanterol) as a once-daily inhaled treatment for asthma in adults, but said the medicine was not ready for primetime in adolescents with the disease.
You may also be interested in...
FDA Pulmonary/Rheumatology Division Sees Management Shakeup
Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Need a specific report? 1000+ reports available
Buy Reports